Final results from the trials of Moderna’s vaccine against Covid-19 confirm it has 94% efficacy and nobody who was vaccinated with it developed the severe disease, says the company, kickstarting the approval process with regulators around the world.

Axar.az reports that the US company is submitting the data to the regulators in the US, Europe, and the UK for an emergency license. It expects the Food and Drug Administration in the US to consider it at its meeting on 17 December, Moderna said.

The UK has bought 7m doses of the vaccine – 5m on the day Moderna announced its interim result of 94.5% efficacy and a further 2m last week. But supplies of the vaccine to the UK are not expected until March. Moderna, based in Massachusetts, has received $2.48bn in US federal funds and was a key part of the Trump administration's Operation Warp Speed.